A Story That Defies the Script
Imagine sitting in a sterile room, fluorescent lights buzzing, as your oncologist leans forward with the same grave tone he’s likely used dozens of times that month:
"Stage 4 prostate cancer. Incurable, but manageable."
Manageable. That’s medical code for hormone blockers that thin your bones, wreck your libido, fog your brain, and leave you clutching hope in six-month increments. Manageable means a handful of pills worth tens of thousands of dollars a month—pills designed not to cure, but to delay the inevitable slide.
For Jeffrey Kramer of Shelby, Ohio, that was not enough. A civil fraud attorney by trade, he had spent his life fighting Goliaths on behalf of the powerless. When cancer came for him, he refused to simply accept “management” as a euphemism for surrender.
Fifteen weeks later, the story flipped.
A PET scan expected to light up like a battlefield came back blank. No hot spots in his hips. None in his spine. None in his lymph nodes. No evidence of active cancer.
The radiologist, so conditioned to finding bad news, sat on the report for a week before admitting it: clean.
Total cost? About $20,000.
Side effects? None.
Outcome? A man who should have been preparing his will was preparing to live.
This isn’t a Hollywood script. It’s Jeffrey’s real story—splashed across ZeroHedge and American Greatness—and it’s igniting a grassroots medical insurgency.
The Spark: A Protocol Buried in Plain Sight
What Jeffrey followed wasn’t random. His treatment was based on a peer-reviewed protocol published in the Journal of Orthomolecular Medicine in September 2024:
“Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol.”
Sixteen physicians and researchers across the US, Canada, and Europe—among them Dr. Pierrick Martinez and Dr. Paul Marik—pulled together 204 studies to craft something bold.
This wasn’t another miracle herb or “miracle berry” scam. It was a blueprint, grounded in biochemistry, for attacking cancer’s overlooked weakness: dysfunctional mitochondria in cancer stem cells.
Cancer’s Hidden Weakness: Mitochondria Gone Rogue
Most of us grew up on the “bad genes” theory of cancer, also known as the somatic mutation theory. Cancer, we’re told, is just DNA gone haywire, an unlucky lottery of mutations that trigger uncontrolled growth.
But the Mitochondrial-Stem Cell Connection (MSCC) theory tells a different story.
Your stem cells—the body’s repair crew—depend on healthy mitochondria (the power plants of the cell) to function.
When those mitochondria suffer chronic damage, they stop producing clean energy and start leaking oxidative chaos.
That chaos mutates the stem cells into cancer stem cells (CSCs)—the near-immortal seeds of tumors that resist chemo, dodge radiation, and laugh at targeted drugs.
Chemo may shrink the tumor, but if CSCs survive, the cancer comes roaring back.
The protocol’s genius is this: instead of trying to nuke cancer into submission, it starves and sabotages CSCs—forcing them to sober up metabolically or die.
The 15-Week Battle Plan
Jeffrey’s regimen wasn’t guesswork. It was six carefully layered interventions designed to corner CSCs from every angle. Here’s the breakdown:
1. Therapeutic Ketogenic Diet
Purpose: Starves CSCs of glucose, their preferred junk food. Fuels healthy cells with ketones.
Implementation:
<50g carbs/day.
High fat, moderate protein (avocados, fatty fish, eggs, olive oil).
Optional intermittent fasting (16:8).
Why it works:
Trials show keto slows glioblastoma and pancreatic cancer.
A UCSF study showed keto makes chemo more effective by sabotaging cancer metabolism.
2. Moderate Exercise
Purpose: Enhances mitochondrial repair and immune surveillance.
Implementation:
45–75 minutes, 3x/week.
Aerobic zone: brisk walk, swim, cycling.
Mix steady-state with short bursts (“press-pulse” therapy).
Why it works:
Exercise revs OxPhos, repairing mitochondria.
Studies show regular activity lowers cancer recurrence risk by 30–40%.
3. High-Dose IV Vitamin C
Purpose: Generates hydrogen peroxide inside tumors, selectively frying CSCs.
Implementation:
25–75g IV, 3x/week (via port/PICC).
Why it works:
Orthomolecular gold standard, tested in multiple trials.
Safe at high doses, non-toxic to healthy cells.
Data show slowed progression in ovarian, pancreatic cancers.
4. Ivermectin
Purpose: Disrupts CSC signaling, halts metastasis.
Implementation:
1 mg/kg daily (70–90mg/day for most adults).
Why it works:
Nobel Prize-winning antiparasitic with dozens of PubMed cancer studies.
Blocks Wnt/β-catenin, the pathway CSCs use to spread.
Reported remissions in rectal, ovarian, bladder cancers.
5. Fenbendazole (or Mebendazole)
Purpose: Microtubule disruptor + glutamine blocker.
Implementation:
222–444 mg/day (Panacur-C packets).
Why it works:
Originally a veterinary dewormer, now studied in human cancers.
Induces apoptosis in lung, ovarian, breast lines.
Synergizes with ivermectin: documented 70% drops in CEA tumor markers.
6. Vitamins & Minerals
Purpose: Cofactors for mitochondrial repair.
Implementation:
Vitamin D: 5,000 IU/day
Vitamin K2: 100 mcg/day
Zinc: 30 mg/day
Magnesium: 400 mg/day
Potassium: food sources preferred, monitor levels.
Why it works:
Deficiencies feed cancer’s survival advantage.
Correcting them enhances metabolic resilience.
Safety Note
Every two weeks: check CBC, kidney, liver, electrolytes. Adjust dosing under physician supervision.
Beyond Jeffrey: A Growing Wave
Jeffrey’s story isn’t unique anymore. Across X (Twitter), forums, and private groups:
Dr. William Makis (McGill-trained oncologist) shares near-daily remissions and dramatic tumor marker declines.
Patients report “incurable” cancers stalling, shrinking, or vanishing.
Videos rack up millions of views—people whispering, what if this really works?
PubMed is now stacked with ivermectin’s anti-cancer arsenal (bladder, breast, gliomas) and fenbendazole’s apoptosis data. Keto diets are under clinical trial for glioblastoma. IV Vitamin C has NIH-funded studies.
This is no longer fringe chatter—it’s evidence hiding in plain sight.
The Elephant in the Room: Why Isn’t This Everywhere?
Three words: No profit margin.
Ivermectin: pennies a pill.
Fenbendazole: sold at Tractor Supply.
Vitamin C: off-patent for decades.
Keto: free if you have discipline.
None of these can sustain the $200 billion oncology market built on patented drugs.
FDA approval would require $100M+ trials with no ROI. Which means—unless a philanthropist bankrolls it—patients are left to self-navigate.
That’s the tragedy. A therapy with documented remissions may be locked out of the mainstream because it threatens the wrong revenue streams.
Practical Guidance for Patients
If you’re staring down cancer—or supporting someone who is—here’s how to move from curiosity to action:
Get Medical Oversight
Seek out functional or integrative oncologists (Dr. Makis lists allies).
Don’t wing dosages alone—labs matter.
Track Markers
Tumor markers (CEA, CA-125, PSA, etc.).
Inflammatory markers (CRP, LDH).
Imaging at baseline and 3 months.
Start with Diet & Lifestyle
Keto + exercise alone reduce recurrence risk dramatically.
Layer in IV Vitamin C, then carefully add repurposed drugs under supervision.
Join the Community
Hashtag #HybridOrthomolecular is where patients share protocols.
Peer networks provide moral support and sourcing tips.
Push for Trials
Contact NCI, advocacy groups.
Share success stories—pressure creates funding.
The Bigger Picture: Hope Reborn
Cancer takes 618,000 American lives every year. Too often, patients die not from the disease itself, but from the collateral damage of “approved” therapies.
This protocol doesn’t promise perfection. But it offers something many haven’t had in decades: a fighting chance without being destroyed in the process.
Jeffrey’s story is a reminder: medicine doesn’t always move forward from billion-dollar labs. Sometimes, it’s cobbled together by brave patients, renegade doctors, and mountains of overlooked science.
Cancer is a thief. But thieves get caught. This protocol may just be the flashlight we’ve been waiting for.
Final Words
If you’re reading this while fighting, know this: you are not alone, and you are not a statistic. There are warriors—patients, doctors, families—refusing to bow to inevitability.
Print this. Share it. Talk to your doctor. Explore the resources. And remember: hope is not helpless.
Sources & Further Reading
Journal of Orthomolecular Medicine (2024): “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment.”
PubMed studies on ivermectin, fenbendazole, and ketogenic therapies.
Clinical anecdotes shared by Dr. William Makis and patient communities online.
Blessings.
Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine
Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)
Subscribe to my newsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile
This is amazing! Thank and sharing it widely. Also, Shanah Tovah to you and your family.